by The Mount Sinai Hospital
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance.
The … Read more
by Kyle Doherty
Investigators are examining and implementing several innovations that they hope will combat the persistent issue of limited access to cancer care for patients living in rural areas, including programs aimed at increasing clinical trial enrollment for these … Read more
Clearity’s Perspective: If you or someone you love has been diagnosed with low-grade serous ovarian cancer (LGSOC), consider watching the recording of the OC Education webinar, “But This is Different: Understanding and Getting Support for the Unique Needs of People … Read more
Clearity’s Perspective: As this article highlights, it is important to know that you can bring up questions or concerns related to your prognosis with someone on your care team. Instead of waiting for the doctor to bring this topic up, … Read more
Clearity Perspective: For some people diagnosed with ovarian cancer, an important part of their “new normal” is returning to work. This can present opportunities and challenges. The impacts of cancer, surgery, and side effects from treatment may make re-entering the … Read more
Danielle Peterson, Clearity’s Director of Education, talks with End-of-Life Doula, Vanessa Johnson, about planning for end-of-life, considerations for a ‘good death,’ and how she compassionately meets individuals and families at the end of life.
To watch the video of the … Read more
by Lauren Comander
Sophia George, Ph.D., and Matthew Schlumbrecht, M.D., M.P.H., are taking on the world of ovarian cancer research. As researchers for Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, the duo is
… Read moreby Chris Ryan
TORL-1-23, a Claudin-6 (CLDN6)–targeted antibody-drug conjugate (ADC), led to responses in patients with heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer. Additionally, the agent was well tolerated, according to data from the phase 1 TORL-123-001 … Read more
by Rose McNulty
Mirvetuximab soravtansine showed promise for patients with heavily pretreated FRα-positive, platinum-sensitive ovarian cancer—a challenging patient population to treat—in the phase 2 PICCOLO trial. New data from the study presented at the European Society for Medical Oncology (ESMO) … Read more
by Jason M. Broderick
The TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) showed promising antitumor activity with manageable toxicity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy, according to results from the phase 2 TROPION-PanTumor03 … Read more
At the ESMO Congress 2024 (Barcelona, 13–17 September), final overall survival (OS) data after a median follow-up of approximately 6 years revealed no benefit of niraparib maintenance over placebo for patients newly diagnosed with advanced ovarian cancer at high risk … Read more
By Linda Winkler Garvin
Clearity’s Perspective: Linda Winkler Garvin has a Masters degree in nursing, adult nurse practitioner training, and over 30 years of healthcare experience. Her story is an example of how even those with a medical background may … Read more
By Linda Winkler Garvin
Clearity’s Perspective: Linda Winkler Garvin has a Masters degree in nursing, adult nurse practitioner training, and over 30 years of healthcare experience. Her story is an example of how even those with a medical background may … Read more
by Barbra Williams Cosentino
If your doctor said, “I’m very sorry, but your cancer is terminal,” you’d obviously be devastated. What if she then added, “The prognosis is that you have about six months left, but with treatments we can … Read more
by Kyle Doherty
A research statement was published by the American Society of Clinical Oncology (ASCO) that describes 4 recommendations for decentralization to improve accessibility of cancer clinical trials.1,2
In the statement, the ASCO panel recommended that the FDA … Read more
Denise’s wife of 33 years, Michelle, lived with ovarian cancer for 13 years. She went through six kinds of chemo, two kinds of radiation, and three clinical trials. But her ovarian cancer came back again and again. She died in … Read more
by University of Birmingham
A study published in the International Journal of Gynecological Cancer found that the UK’s protocol for picking up early-stage disease in women with high grade serous ovarian cancer—the most common, aggressive, and lethal form of the … Read more
by Jax DiEugenio
Although the risks of cancer developing in females harboring germline BRCA1or BRCA2 mutations are understood and have propelled genetic testing and preventative measures for this population, more work is required to amplify the rates of this … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
